Literature DB >> 7855229

Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron.

E C Warburton1, M H Joseph, J Feldon, I Weiner, J A Gray.   

Abstract

Latent inhibition (LI) is a behavioural phenomenon whereby preexposure to a stimulus without reinforcement interferes with the formation of subsequent associations to that stimulus. Using preexposure to a tone stimulus which subsequently serves as a conditioned stimulus for suppression of licking, we have confirmed that LI is disrupted by a low dose of amphetamine. Haloperidol was able to prevent this effect of amphetamine. Ondansetron, a selective and potent 5HT3 receptor antagonist, was also shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. In addition, it was demonstrated that ondansetron could enhance LI; using only ten preexposures, no LI was obtained in the saline group, but was apparent in animals given ondansetron, an effect which has been previously shown with haloperidol. Haloperidol, at the higher dose used, reduced suppression of licking, however, ondansetron at the effective dose had no such effect. It is concluded that ondansetron is able to attenuate increases in dopamine activity, produced pharmacologically with amphetamine without affecting baseline dopamine activity. The implications of these findings for a possible antipsychotic action of ondansetron are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7855229     DOI: 10.1007/bf02244998

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

1.  Antagonism of Low Dose Amphetamine Disruption of Latent Inhibition in Rats By Haloperidol, and By the 5Ht-3 Antagonist, Ondansetron: Warburton EC, Feldon J*, Weiner I*, Gray JA, Joseph MH MRC Brain, Behaviour and Psychiatry Research Group, Dept of Psychology, Institute of Psychiatry, London, SE5 8AF and *Dept of Psychology, University of Tel Aviv, Israel.

Authors: 
Journal:  J Psychopharmacol       Date:  1992-01       Impact factor: 4.153

2.  Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man.

Authors:  N S Gray; A D Pickering; D R Hemsley; S Dawling; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

Authors:  G J Kilpatrick; B J Jones; M B Tyers
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

4.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

5.  Latent inhibition of conditioned dopamine release in rat nucleus accumbens.

Authors:  A M Young; M H Joseph; J A Gray
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

6.  Latent inhibition and blocking: further consideration of their construct validity as animal models of schizophrenia Commentary on Ellenbroek and Cools "Animal models with construct validity for schizophrenia"

Authors:  M.H. Joseph; S.H. Jones
Journal:  Behav Pharmacol       Date:  1991-12       Impact factor: 2.293

7.  Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.

Authors:  M Koulu; J Lappalainen; J Hietala; B Sjöholm
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: relationship to schizophrenic attention disorder.

Authors:  P R Solomon; A Crider; J W Winkelman; A Turi; R M Kamer; L J Kaplan
Journal:  Biol Psychiatry       Date:  1981-06       Impact factor: 13.382

9.  Long-term attentional deficit in nonhandled males: possible involvement of the dopaminergic system.

Authors:  J Feldon; I Weiner
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 10.  Amphetamine psychosis and schizophrenia: a dual model.

Authors:  L Kokkinidis; H Anisman
Journal:  Neurosci Biobehav Rev       Date:  1981       Impact factor: 8.989

View more
  16 in total

1.  Latent inhibition: interpretation of amphetamine effects in novel paradigms.

Authors:  M H Joseph
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

2.  Effects of nicotine and amphetamine on latent inhibition in human subjects.

Authors:  J C Thornton; S Dawe; C Lee; C Capstick; P J Corr; P Cotter; S Frangou; N S Gray; M A Russell; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

4.  Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.

Authors:  Axel Becker; Gisela Grecksch; Gerald Zernig; Elisabeth Ladstaetter; Christoph Hiemke; Ulrich Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2008-09-23       Impact factor: 4.530

5.  Haloperidol and clozapine antagonise amphetamine-induced disruption of latent inhibition of conditioned taste aversion.

Authors:  Holger Russig; Aneta Kovacevic; Carol A Murphy; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

6.  Differences in serotonin and dopamine metabolism in the rat brain in latent inhibition.

Authors:  G F Molodtsova
Journal:  Neurosci Behav Physiol       Date:  2003-03

7.  Enhanced latent inhibition in dopamine receptor-deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action.

Authors:  Cecilie Bay-Richter; Colm M P O'Tuathaigh; Gerard O'Sullivan; David M Heery; John L Waddington; Paula M Moran
Journal:  Int J Neuropsychopharmacol       Date:  2008-11-17       Impact factor: 5.176

8.  Prenatal and postnatal maternal contributions in the infection model of schizophrenia.

Authors:  Urs Meyer; Severin Schwendener; Joram Feldon; Benjamin K Yee
Journal:  Exp Brain Res       Date:  2006-03-22       Impact factor: 1.972

9.  Withdrawal from continuous amphetamine administration abolishes latent inhibition but leaves prepulse inhibition intact.

Authors:  Daria Peleg-Raibstein; Esther Sydekum; Holger Russig; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2006-02-10       Impact factor: 4.530

10.  Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.

Authors:  L M McDonald; P M Moran; G N Vythelingum; M H Joseph; J D Stephenson; J A Gray
Journal:  Psychopharmacology (Berl)       Date:  2002-08-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.